Related Experiment Videos
[Evaluation of individual sensitivity to levamisole in children with asthmatic bronchitis]
Sovetskaia Meditsina
|January 1, 1990
Insights
Individual sensitivity to the immunostimulant levamisole can be determined by measuring blood plasma cyclic nucleotides (cAMP/cGMP). This approach helps optimize therapy for children with asthmatic bronchitis.
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Context:
- Asthmatic bronchitis is a common respiratory condition in children.
- Levamisole is an immunostimulant drug used in certain therapeutic contexts.
- Individual responses to medications can vary significantly.
Purpose:
- To establish a method for predicting individual sensitivity to levamisole.
- To correlate cyclic nucleotide levels with drug response.
- To enhance the therapeutic efficacy of levamisole in pediatric patients.
Summary:
- Blood plasma cyclic nucleotide levels, specifically the cAMP/cGMP coefficient, can serve as a biomarker for individual sensitivity to levamisole.
- Measurement and computation of this coefficient offer a quantitative approach to assess patient response.
- This biomarker aids in tailoring levamisole treatment for children with asthmatic bronchitis.
Impact:
- Enables personalized medicine approaches for levamisole therapy.
- Potentially improves treatment outcomes and reduces adverse effects in pediatric patients.
- Provides a biochemical basis for understanding individual drug responses in immunological treatments.
Abstract:
Individual sensitivity to levamisole, an immunostimulant, may be tested by measurement of the blood plasma cyclic nucleotides and computation of the cAMP/cGMP coefficient. Detection of individual sensitivity to this drug in children suffering from asthmatic bronchitis contributes to the therapy efficacy.